-Allergan Inc. announced on Tuesday that it received approval from the US Food and Drug Administration (FDA) to market Restasis (cyclosporine ophthalmic emulsion, 0.05%) to patients with keratoconjunctivitis sicca (KCS).
Allergan said the FDA approval was based on a phase III study, demonstrating that use of Restasis resulted in clinically relevant increases in Schirmer wetting versus other potential treatments such as topical anti-inflammatory drugs or using punctal plugs.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!